NCT03926624: Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage |
|
|
| Recruiting | 3 | 450 | US | DFP-10917, Cytarabine, Azacitidine, Decitabine, Mitoxantrone, Etoposide, Fludarabine, Idarubicin, Venetoclax, Cladribine | Delta-Fly Pharma, Inc. | Leukemia, Myeloid, Acute | 12/22 | 12/22 | | |